Phase 2 Sickle Cell Disease Trial, Recruiting NCT07616154 Sponsor: St. Jude Children's Research Hospital Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Phase 2 Sickle Cell Disease Trial, Recruiting

NCT07616154
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

For the person receiving the transplant (recipient):

  • People aged 22 years or younger.
  • People who do not have a fully matched sibling donor available, but do have a partially matched (at least half-matched) family member who is willing to donate stem cells.
  • People who have been diagnosed with sickle cell disease (any type) AND meet at least one of the following:
  • A history of abnormal blood flow readings in the brain (measured by a specific ultrasound test called a transcranial Doppler) on at least two separate occasions.
  • A history of a stroke or silent stroke shown on a brain MRI.
  • Two or more episodes of a serious lung complication called acute chest syndrome in the past two years.
  • Two or more severe pain crises requiring intravenous pain medication in the past 12 months.
  • Two or more episodes of a prolonged, painful erection lasting 4 hours or more, or requiring emergency medical care.
  • Regular blood transfusions, meaning 8 or more transfusions in the past 12 months.
  • Worsening damage to organs (such as the heart, kidneys, or lungs) that at least two independent blood specialists have agreed in writing is not responding to other treatments and may benefit from a stem cell transplant.

For the donor:

  • A family member who is at least a partial (half) match to the recipient.
  • Someone who has tested negative for HIV.
  • Someone who is not pregnant (confirmed by a blood or urine test within 14 days before joining).
  • Someone who is not breastfeeding.
  • Someone who does not have a significant blood disorder affecting haemoglobin — note that having sickle cell trait (carrying one copy of the gene, not the disease itself) is acceptable.
  • Someone who has completed the required donor health and safety assessment process, or for whom the lead doctor has documented an urgent medical need (confirm with trial site).

Who may not be able to join:

For the person receiving the transplant (recipient):

  • People with a low general health or ability to function score (below 60 on standard medical scales).
  • People who are currently pregnant (confirmed by a blood or urine test within 14 days before joining).
  • People who are currently breastfeeding.
  • People with an active, uncontrolled infection (bacterial, viral, or fungal) that is getting worse despite treatment, within one month before starting the pre-transplant treatment — people with a minor or suspected infection should wait until it resolves.
  • People with confirmed HIV infection.
  • People with significantly elevated liver function levels in the blood, specifically a type called conjugated (direct) bilirubin more than three times the normal upper limit for their age — though people whose levels are raised due to a specific reaction to blood transfusions may still be eligible if the levels are coming back down (confirm with trial site).
  • People whose heart is not pumping strongly enough, based on an ultrasound of the heart.
  • People whose kidneys are not filtering blood well enough (below a certain threshold on a standard kidney function measure).
  • People whose lungs are not working well enough, based on breathing tests or blood oxygen levels.
  • People who have developed antibodies that specifically target the donor's tissue type, if those antibodies cannot be reduced with treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Akshay Sharma, MD, St. Jude Children's Research Hospital

Phone: 8662785833

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
St. Jude Children's Research Hospital
Registry
ClinicalTrials.gov
Start date
1 September 2026
Est. completion
1 September 2034

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

GVHD-free and rejection free survival (GRFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov